OptiBiotix Health plc (AIM: OPTI) reported strong revenue and margin growth in its audited results for 2025 as the company continued expanding international sales of its weight management and gut health products.
Revenue increased 34% to £1.17 million from £870,000 a year earlier, with a further £212,000 of orders received during 2025 deferred into 2026 deliveries.
Gross profit rose 85% to £614,000, while gross margin improved significantly to 53% from 38%, reflecting improved product mix and operational efficiencies.
The company ended the year with cash balances of £1.04 million and no debt, alongside holdings in ProBiotix Health Plc and SkinBioTherapeutics Plc valued at a combined £6.45 million at year-end.
Operationally, OptiBiotix highlighted the launch of SlimBiome within Hydroxycut, which markets itself as the leading weight-loss supplement brand in the US.
The company also secured a distribution agreement with a major direct-selling weight management group, with product launch scheduled for the first half of 2026.
International growth continued to accelerate, particularly across Asia where revenues rose 182% to £268,000. Overseas markets now account for 73% of total revenues compared with 63% the previous year.
OptiBiotix also announced progress in its SweetBiotix platform after introducing an enzyme-based manufacturing process designed to improve product purity, taste and production efficiency while significantly reducing costs.
Post period-end trading remained strong, with the company reporting more than £800,000 of orders received during January 2026 alone, including a 24 metric tonne SlimBiome order from Taiwanese distributor Meelung Trading.
The company also confirmed that Hull University Teaching Hospitals NHS Trust has commenced a clinical study evaluating the effect of WellBiome consumption before surgery on intensive care demand and potential NHS cost savings.
Management said the business is now shifting away from broad expansion spending towards a more commercially focused strategy aimed at achieving sustainable profitability.
This includes targeted reductions in marketing, R&D and intellectual property costs expected to save between £500,000 and £600,000 annually, alongside initiatives expected to cut SlimBiome production costs by up to 48%.
Chief executive Stephen O’Hara said the company had completed major investment in its intellectual property, manufacturing base and international distribution infrastructure and is now focused on accelerating commercial sustainability while scaling high-growth product areas.
